do the DD
Motley Fool 12/6/13
There will be plenty of upside when imetelstat shows favorable results in a mid-stage trial on Monday.
Analyst Rating Network 12/4/13
Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK)
Consensus Price Target: $11.00 (151.14% upside)
Fly On The Wall: Jefferies Out With $ 190 Target On TSLA *** POSTED ***
Fly On the Wall 12/3/13
December 3, 2013
08:37 EDT TSLA Jefferies views Tesla news on German conclusion as positive
Jefferies thinks last night's news that the German Federal Motor Transport Authority came to a favorable conclusion in its investigation of the recent Model S fires should bring confidence that the NHTSA investigation will result in a similar favorable outcome. Jefferies thinks negative news is priced into Tesla shares and keeps a Buy rating with $190 price target
covered and long.
Analyst Rating Network ( FB ) to verify